REGULATORY

• Japan Panel to Review Ferring Gene Therapy, Fujifilm Cell Product on April 20
  April 14, 2026

• LDP, Ishin to Explore Role of Private Insurance in Reform Talks
  April 14, 2026

• Middle East War Hitting API Air Freight, Trade Group Warns
  April 13, 2026

• Japan’s 19th Pharmacopoeia Revision Takes Effect
  April 13, 2026

• Voranigo and More Meds Missing from April Listing Slate; Servier Plans Packaging Change
  April 10, 2026

• Health Insurance Reform Bill Enters Diet Debate; OTC-Like Drug Charges in Focus
  April 10, 2026

• CEPI Seeks Continued Technology, Funding Ties with Japan
  April 10, 2026

• Dialysis Tubing and Medical Device Makers Fret over Long-Term Supply Risks
  April 10, 2026

• Japan Moves to Bypass Wholesalers in Fuel Supply to Hospitals
  April 10, 2026

• Japan OKs Listing of Exdensur, Aquipta, Tukysa, and More; New Price Rules Applied to Two
  April 9, 2026

• Briviact Set for Price Cut with CEA Adjustment Rate of 0.1
  April 9, 2026

• Chuikyo Sets Reimbursement Pathways for Five Regenerative Medicine Products
  April 9, 2026

• Chuikyo Names Hosei Prof. Sugahara to Drug Pricing, CEA Panels
  April 9, 2026

• MHLW Publishes Updated LLP List with Higher Surcharges from June
  April 8, 2026

• Uncertainty Clouds Start of 6-Month CEA “Technical Discussions”
  April 7, 2026

• Pfizer Japan Chief Urges Applying 9.6% Growth Target to Domestic Market
  April 7, 2026

• Japan Identifies 28 New “Drug Loss” Products from 2021-23 Approvals
  April 7, 2026

• Japan OKs Zolgensma Intrathecal Form, Breyanzi Expansion, New EB Therapy
  April 6, 2026

• Trump Signs Off on Up to 100% Tariffs on Drugs; Japan Rate Set at 15%
  April 3, 2026

• Japan Launches Task Force to Secure Critical Supplies amid Middle East Crisis
  April 3, 2026

ページ

• « 先頭
• ‹ Prev
• 1
• 2
• 3
• 4
• 5
• 6
• 7
• 8
• 9
• …
• Next ›
• 最終 »